| __timestamp | Intra-Cellular Therapies, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 612613000000 |
| Thursday, January 1, 2015 | 18187286 | 650773000000 |
| Friday, January 1, 2016 | 24758063 | 619061000000 |
| Sunday, January 1, 2017 | 23666957 | 628106000000 |
| Monday, January 1, 2018 | 30099855 | 717599000000 |
| Tuesday, January 1, 2019 | 64947625 | 964737000000 |
| Wednesday, January 1, 2020 | 186363444 | 875663000000 |
| Friday, January 1, 2021 | 272611040 | 886361000000 |
| Saturday, January 1, 2022 | 358782000 | 997309000000 |
| Sunday, January 1, 2023 | 409864000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants and emerging players is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Intra-Cellular Therapies, Inc., a burgeoning innovator, present a fascinating study in contrasts through their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.
Takeda's SG&A expenses have shown a steady increase, peaking at over 1 trillion yen in 2023, reflecting a strategic expansion and robust market presence. In contrast, Intra-Cellular Therapies has experienced a dramatic rise in SG&A expenses, growing nearly 40 times from 2014 to 2023, indicative of aggressive growth and market penetration strategies.
This financial narrative underscores the diverse approaches within the pharmaceutical sector, where established giants and ambitious newcomers navigate their paths to success.
Eli Lilly and Company vs Intra-Cellular Therapies, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: AbbVie Inc. vs Intra-Cellular Therapies, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Insmed Incorporated
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Verona Pharma plc
Breaking Down SG&A Expenses: Takeda Pharmaceutical Company Limited vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Perrigo Company plc
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Galapagos NV
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and MiMedx Group, Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs BioMarin Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc.